Transcription factor NF‑YA promotes a malignant phenotype by upregulating fatty acid synthase expression

Guo,Jing; Kong,Ling Min; Peng,Ai Fen; Long,Xin Hua; Zhou,Yang; Shu,Yong

doi:10.3892/mmr.2016.5897

Transcription factor NF‑YA promotes a malignant phenotype by upregulating fatty acid synthase expression

Authors:
- Jing Guo
- Ling Min Kong
- Ai Fen Peng
- Xin Hua Long
- Yang Zhou
- Yong Shu
View Affiliations

Affiliations: Department of Oral and Maxillofacial Surgery, The Affiliated Stomatological Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Department of Orthopedics, The Central People's Hospital of Ji'an City, Ji'an, Jiangxi 343000, P.R. China, Jiangxi University of Traditional Chinese Medicine, Nanchang, Jiangxi 330004, P.R. China, Department of Orthopedics, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China
Published online on: October 27, 2016 https://doi.org/10.3892/mmr.2016.5897
Pages: 5007-5014
Copyright: © Guo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recent studies have revealed that increased expression of the alpha subunit of nuclear transcription factor Y (NF‑YA) is associated with the malignant phenotype of various tumors. However, whether elevated expression of NF‑YA promotes a malignant phenotype in osteosarcoma (OS), and the molecular mechanisms underlying this predicted effect is currently unknown. In the present study, small hairpin RNA (shRNA)‑mediated knockdown of endogenous NF‑YA significantly inhibited the migration and invasion capabilities of OS cells in vitro, whereas ectopic expression of NF‑YA increased the migration and invasion capabilities of these cells. In addition, the induction of upregulated NF‑YA expression on the malignant phenotype of OS cells was attenuated by silencing fatty acid synthase (FASN) expression. Furthermore, the expression level of FASN was increased by upregulating NF‑YA, while decreased FASN expression was observed following NF‑YA silencing in OS cells. The results of the present study suggest that NF‑YA may promote a malignant phenotype in OS cells, in part, by activating the FASN signaling pathway, which may represent a promising target for the management of OS.

View Figures

View References

1	Salah S, Ahmad R, Sultan I, Yaser S and Shehadeh A: Osteosarcoma with metastasis at initial diagnosis: Current outcomes and prognostic factors in the context of a comprehensive cancer center. Mol Clin Oncol. 2:811–816. 2014.PubMed/NCBI
2	Lewis VO: What's new in musculoskeletal oncology. J Bone Joint Surg Am. 91:1546–1556. 2009. View Article : Google Scholar : PubMed/NCBI
3	Iwamoto Y, Tanaka K, Isu K, Kawai A, Tatezaki S, Ishii T, Kushida K, Beppu Y, Usui M, Tateishi A, et al: Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J. J Orthop Sci. 14:397–404. 2009. View Article : Google Scholar : PubMed/NCBI
4	Cho Y, Jung GH, Chung SH, Kim JY, Choi Y and Kim JD: Long-term survivals of stage IIb osteosarcoma: A 20-year experience in a single institution. Clin Orthop Surg. 3:48–54. 2011. View Article : Google Scholar : PubMed/NCBI
5	Bölling T, Schuller P, Distelmaier B, Schuck A, Ernst I, Gosheger G, Winkelmann W, Dirksen U, Jürgens H, Kronholz HL, et al: Perioperative high-dose rate brachytherapy using a bendy applicator (flab): Treatment results of 74 patients. Anticancer Res. 28:3885–3890. 2008.PubMed/NCBI
6	Lourda M, Trougakos IP and Gonos ES: Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of Clusterin/Apolipoprotein J. Int J Cancer. 120:611–622. 2007. View Article : Google Scholar : PubMed/NCBI
7	Schwartz CL, Gorlick R, Teot L, Krailo M, Chen Z, Goorin A, Grier HE, Bernstein ML and Meyers P: Children's Oncology Group: Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group. J Clin Oncol. 25:2057–2062. 2007. View Article : Google Scholar : PubMed/NCBI
8	Chou AJ and Gorlick R: Chemotherapy resistance in osteosarcoma: Current challenges and future directions. Expert Rev Anticancer Ther. 6:1075–1085. 2006. View Article : Google Scholar : PubMed/NCBI
9	Dean M, Fojo T and Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005. View Article : Google Scholar : PubMed/NCBI
10	Dolfini D, Gatta R and Mantovani R: NF-Y and the transcriptional activation of CCAAT promoters. Crit Rev Biochem Mol Biol. 47:29–49. 2012. View Article : Google Scholar : PubMed/NCBI
11	Mojsin M, Topalovic V, Vicentic J Marjanovic and Stevanovic M: Transcription factor NF-Y inhibits cell growth and decreases SOX2 expression in human embryonal carcinoma cell line NT2/D1. Biochemistry (Mosc). 80:202–207. 2015. View Article : Google Scholar : PubMed/NCBI
12	Garipov A, Li H, Bitler BG, Thapa RJ, Balachandran S and Zhang R: NF-YA underlies EZH2 upregulation and is essential for proliferation of human epithelial ovarian cancer cells. Mol Cancer Res. 11:360–369. 2013. View Article : Google Scholar : PubMed/NCBI
13	Bungartz G, Land H, Scadden DT and Emerson SG: NF-Y is necessary for hematopoietic stem cell proliferation and survival. Blood. 119:1380–1389. 2012. View Article : Google Scholar : PubMed/NCBI
14	Zhang HT, Zhang D, Zha ZG and Hu CD: Transcriptional activation of PRMT5 by NF-Y is required for cell growth and negatively regulated by the PKC/c-Fos signaling in prostate cancer cells. Biochim Biophys Acta. 1839:1330–1340. 2014. View Article : Google Scholar : PubMed/NCBI
15	Ma H, Yue X, Gao L, Liang X, Yan W, Zhang Z, Shan H, Zhang H, Spear BT and Ma C: ZHX2 enhances the cytotoxicity of chemotherapeutic drugs in liver tumor cells by repressing MDR1 via interfering with NF-YA. Oncotarget. 6:1049–1063. 2015. View Article : Google Scholar : PubMed/NCBI
16	Shi Z, Chiang CI, Labhart P, Zhao Y, Yang J, Mistretta TA, Henning SJ, Maity SN and Mori-Akiyama Y: Context-specific role of SOX9 in NF-Y mediated gene regulation in colorectal cancer cells. Nucleic Acids Res. 43:6257–6269. 2015. View Article : Google Scholar : PubMed/NCBI
17	Liu ZL, Wang G, Peng AF, Luo QF, Zhou Y and Huang SH: Fatty acid synthase expression in osteosarcoma and its correlation with pulmonary metastasis. Oncol Lett. 4:878–882. 2012.PubMed/NCBI
18	Liu ZL, Mao JH, Peng AF, Yin QS, Zhou Y, Long XH and Huang SH: Inhibition of fatty acid synthase suppresses osteosarcoma cell invasion and migration via downregulation of the PI3K/Akt signaling pathway in vitro. Mol Med Rep. 7:608–612. 2013.PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Hackenberg D, Wu Y, Voigt A, Adams R, Schramm P and Grimm B: Studies on differential nuclear translocation mechanism and assembly of the three subunits of the Arabidopsis thaliana transcription factor NF-Y. Mol Plant. 5:876–888. 2012. View Article : Google Scholar : PubMed/NCBI
21	Ying S, Dunnebier T, Si J and Hamann U: Estrogen receptor alpha and nuclear factor Y coordinately regulate the transcription of the SUMO-conjugating UBC9 gene in MCF-7 breast cancer cells. PLoS One. 8:e756952013. View Article : Google Scholar : PubMed/NCBI
22	Belluti S, Basile V, Benatti P, Ferrari E, Marverti G and Imbriano C: Concurrent inhibition of enzymatic activity and NF-Y-mediated transcription of Topoisomerase-IIα by bis-DemethoxyCurcumin in cancer cells. Cell Death Dis. 4:e7562013. View Article : Google Scholar : PubMed/NCBI
23	Lützner N, De-Castro Arce J and Rösl F: Gene expression of the tumour suppressor LKB1 is mediated by Sp1, NF-Y and FOXO transcription factors. PLoS One. 7:e325902012. View Article : Google Scholar : PubMed/NCBI
24	Yamanaka K, Mizuarai S, Eguchi T, Itadani H, Hirai H and Kotani H: Expression levels of NF-Y target genes changed by CDKN1B correlate with clinical prognosis in multiple cancers. Genomics. 94:219–227. 2009. View Article : Google Scholar : PubMed/NCBI
25	Uemoto Y, Abe T, Tameoka N, Hasebe H, Inoue K, Nakajima H, Shoji N, Kobayashi M and Kobayashi E: Whole-genome association study for fatty acid composition of oleic acid in Japanese Black cattle. Anim Genet. 42:141–148. 2011. View Article : Google Scholar : PubMed/NCBI
26	Bian Y, Yu Y, Wang S and Li L: Up-regulation of fatty acid synthase induced by EGFR/ERK activation promotes tumor growth in pancreatic cancer. Biochem Biophys Res Commun. 463:612–617. 2015. View Article : Google Scholar : PubMed/NCBI
27	Bauerschlag DO, Maass N, Leonhardt P, Verburg FA, Pecks U, Zeppernick F, Morgenroth A, Mottaghy FM, Tolba R, Meinhold-Heerlein I and Bräutigam K: Fatty acid synthase overexpression: Target for therapy and reversal of chemoresistance in ovarian cancer. J Transl Med. 13:1462015. View Article : Google Scholar : PubMed/NCBI
28	Grube S, Dunisch P, Freitag D, Klausnitzer M, Sakr Y, Walter J, Kalff R and Ewald C: Overexpression of fatty acid synthase in human gliomas correlates with the WHO tumor grade and inhibition with Orlistat reduces cell viability and triggers apoptosis. J Neurooncol. 118:277–287. 2014. View Article : Google Scholar : PubMed/NCBI
29	Agostini M, Almeida LY, Bastos DC, Ortega RM, Moreira FS, Seguin F, Zecchin KG, Raposo HF, Oliveira HC, Amoêdo ND, et al: The fatty acid synthase inhibitor orlistat reduces the growth and metastasis of orthotopic tongue oral squamous cell carcinomas. Mol Cancer Ther. 13:585–595. 2014. View Article : Google Scholar : PubMed/NCBI
30	Zaytseva YY, Harris JW, Mitov MI, Kim JT, Butterfield DA, Lee EY, Weiss HL, Gao T and Evers BM: Increased expression of fatty acid synthase provides a survival advantage to colorectal cancer cells via upregulation of cellular respiration. Oncotarget. 6:18891–18904. 2015. View Article : Google Scholar : PubMed/NCBI
31	Xu H, Fu J, Ha SW, Ju D, Zheng J, Li L and Xie Y: The CCAAT box-binding transcription factor NF-Y regulates basal expression of human proteasome genes. Biochim Biophys Acta. 1823:818–825. 2012. View Article : Google Scholar : PubMed/NCBI
32	Lu YH, Dallner OS, Birsoy K, Fayzikhodjaeva G and Friedman JM: Nuclear Factor-Y is an adipogenic factor that regulates leptin gene expression. Mol Metab. 4:392–405. 2015. View Article : Google Scholar : PubMed/NCBI
33	Hida M, Hamanaka R, Okamoto O, Yamashita K, Sasaki T, Yoshioka H and Matsuo N: Nuclear factor Y (NF-Y) regulates the proximal promoter activity of the mouse collagen α1(XI) gene (Col11a1) in chondrocytes. In Vitro Cell Dev Biol Anim. 50:358–366. 2014. View Article : Google Scholar : PubMed/NCBI
34	Teran-Garcia M, Adamson AW, Yu G, Rufo C, Suchankova G, Dreesen TD, Tekle M, Clarke SD and Gettys TW: Polyunsaturated fatty acid suppression of fatty acid synthase (FASN): Evidence for dietary modulation of NF-Y binding to the Fasn promoter by SREBP-1c. Biochem J. 402:591–600. 2007. View Article : Google Scholar : PubMed/NCBI